Emerging work has shown that immune checkpoint blockade (ICB) therapy is effective against advanced human cancer; however, only a small subset of cancer patients could benefit from anti-programmed cell death-1/programmed death ligand 1 (anti-PD-1/PD-L1) immunotherapy (11). Here, PDCD1 is linked to cancer.